- Diagnostic Différentiel
- Essayez d'établir votre recherche sur un attribut à la fois, et soyez aussi spécifique que possible! Exemple : "toux chronique".
- Ne pas entrer les résultats multiples tels que "anémie, toux chronique, perte de poids, vomissant" tous en même temps.
- Après sélection de votre attribut, une liste de diagnostics possibles sera générée. Si la liste est trop longue, vous pourrez la réduire en écrivant des attribut additionnels.
- Ne pas écrire les valeurs telles que le "rythme cardiaque 110" ou le "sodium 125", mais plutôt "tachycardie" ou "hyponatrémie".
Drug Information for Loestrin 24 Fe (Warner Chilcott (US), LLC): INDICATIONS AND USAGE
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- INFORMATION FOR THE PATIENT
- ADVERSE REACTIONS
- NONCONTRACEPTIVE HEALTH BENEFITS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- PATIENT BRIEF SUMMARY
- DETAILED PATIENT PACKAGE INSERT
- PRINCIPAL DISPLAY PANEL - CARTON LABEL 1 mg/20 mcg
- Liens externes liés à Loestrin 24 Fe (Warner Chilcott (US), LLC)
Loestrin 24 Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Oral contraceptives are highly effective. Table 2 lists the typical unplanned pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the Norplant® system, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
TABLE 2 Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. United States. Source: Trussell J, Stewart F, Contraceptive Efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology:Seventeenth Revised Edition. New York, NY: Irvington Publishers, 1998.
% of Women Experiencing an UnintendedPregnancy within the First Year of Use
% of Women Continuing Use at One YearAmong couples attempting to avoid pregnancy, the percentage who continue to use a method for one year
Typical UseAmong typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason(2)
Perfect UseAmong couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason(3)
(4) ChanceThe percentage of women becoming pregnant noted in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% became pregnant in one year. This estimate was lowered slightly (to 85%) to represent the percentage that would become pregnant within one year among women now relying on reversible methods of contraception if they abandon contraception altogether 85 85 SpermicidesFoams, creams, gels, vaginal suppositories and vaginal film 26 6 40 Periodic abstinence 25 63 Calendar 9 Ovulation Method 3 Sympto-thermalCervical mucous (ovulation) method supplemented by calendar in the preovulatory and basal body temperature in the postovulatory phases 2 Post-Ovulation 1 CapWith spermicidal cream or jelly Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm 20 6 56 Withdrawal 19 4 CondomWithout spermicides Female (reality) 21 5 56 Male 14 3 61 Pill 5 71 Progestin only 0.5 Combined 0.1 IUD Progesterone T 2.0 1.5 81 Copper T 380A 0.8 0.6 78 LNg 20 0.1 0.1 81 Depo-Provera® 0.3 0.3 70 Norplant® and Norplant® 2 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces risk of pregnancy by at least 75%The treatment schedule is one dose within 72 hours after unprotected intercourse and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1 dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 2 light orange pills), Lo/Ovral® (1 dose is 4 white pills), Triphasil® or Tri-Levlen® (1 dose is 4 yellow pills) Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraceptionHowever, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced or the baby reaches six months of age
In a clinical study, 743 women, 18 to 45 years of age, were treated with Loestrin 24 Fe for up to six 28-day cycles providing a total of 3,823 treatment-cycles of exposure. A total of 583 women completed 6 cycles of treatment. There were a total of 5 on-treatment pregnancies in 3,565 treatment cycles during which no backup contraception was used. The Pearl Index for Loestrin 24 Fe was 1.82.
- Drug Information Provided by National Library of Medicine (NLM).